Byondis B.V. announced positive topline results from the Phase III TULIP\u00ae study, a multi-center, open-label, randomized clinical trial. The trial compared the efficacy and safety of the company\u2019s antibody-drug conjugate (ADC) [vic-]trastuzumab duocarmazine (SYD985) to physician’s choice treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer (MBC).<\/p>\n\n\n\n
The Phase III TULIP study \u201cSYD985 vs. Physician’s Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer\u201d met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement over physician\u2019s choice. PFS is defined as the time from the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurred earlier. The study also demonstrated preliminary supportive overall survival (OS) results.<\/p>\n\n\n\n
\u201cThere is considerable unmet medical need in patients with HER2-positive metastatic breast cancer and [vic-]trastuzumab duocarmazine represents a promising potential clinical advance,\u201d said Byondis Chief Medical Officer Jan Schellens, M.D., Ph.D. \u201cWe are excited by the topline results of TULIP and indebted to all patients who participated in the clinical studies.\u201d<\/p>\n\n\n\n
Byondis CEO Marco Timmers, Ph.D., referred to the study\u2019s culmination as a triumph over adversity. \u201cA large trial involving breast cancer patients with advanced disease is difficult in the best of times, but it is especially challenging during a global pandemic. The completion of TULIP is a testament to the dedication of all involved, especially the patients, their families and participating clinical sites.\u201d<\/p>\n\n\n\n
Detailed results from TULIP will be published at scientific conferences in due course. Byondis will complete the biological license application (BLA) and intends to submit it before the end of 2021.<\/p>\n\n\n\n
With this positive study outcome, Byondis is planning to explore partnerships with pharma and biopharma companies in order to commercialize SYD985 and make it available to patients in need of new treatment options.<\/p>\n\n\n\n
SYD985 was granted fast track designation by the U.S. Food & Drug Administration in January 2018 based on promising data from heavily pre-treated last-line HER2-positive MBC patients participating in a two-part Phase I clinical trial (SYD985.001).<\/p>\n\n\n\n